Regeneron Pharmaceuticals Inc (REGN)

Debt-to-assets ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Long-term debt	US$ in thousands	1,982,900	1,982,600	1,982,200	1,981,800	1,981,400	1,981,100	1,980,700	1,980,400	1,980,000	1,979,600	1,979,200	1,978,900	1,978,500	1,978,300	—	—	0	—	—	—
Total assets	US$ in thousands	33,080,200	32,163,300	30,657,500	30,059,900	29,214,500	27,677,800	27,205,800	26,348,700	25,434,800	23,671,500	21,485,900	17,772,200	17,163,300	16,084,000	14,428,700	15,757,500	14,805,200	13,939,300	13,173,600	12,854,800
Debt-to-assets ratio		0.06	0.06	0.06	0.07	0.07	0.07	0.07	0.08	0.08	0.08	0.09	0.11	0.12	0.12	0.00	0.00	0.00	0.00	0.00	0.00

December 31, 2023 calculation

Debt-to-assets ratio = Long-term debt ÷ Total assets
= $1,982,900K ÷ $33,080,200K
= 0.06

The debt-to-assets ratio of Regeneron Pharmaceuticals, Inc. has been relatively stable over the past eight quarters, fluctuating between 0.08 and 0.10. This ratio indicates the proportion of the company's assets financed by debt. A lower ratio suggests lower financial risk as the company relies less on borrowing to finance its operations. Regeneron's consistently low debt-to-assets ratio suggests that the company has a conservative approach to leverage, with a significant portion of its assets being funded by equity rather than debt. This indicates a strong financial position, as the company has a strong ability to cover its financial obligations using its own resources. Overall, the trend in Regeneron's debt-to-assets ratio reflects a stable and prudent financial management strategy.